Rohto Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	335,801	308,625	270,840	238,664	199,646	181,287
Revenue Growth (YoY)	13.61%	13.95%	13.48%	19.54%	10.13%	-3.74%
Cost of Revenue	147,313	133,686	113,554	101,243	83,157	74,560
Gross Profit	188,488	174,939	157,286	137,421	116,489	106,727
Selling, General & Admin	127,452	115,521	101,377	89,859	76,435	73,933
Research & Development	14,912	14,912	13,390	11,065	8,740	7,903
Amortization of Goodwill & Intangibles	1,523	1,523	436	383	457	372
Operating Expenses	148,395	136,474	117,119	103,883	88,297	84,860
Operating Income	40,093	38,465	40,167	33,538	28,192	21,867
Interest Expense	-1,298	-949	-196	-247	-248	-145
Interest & Investment Income	5,438	1,922	2,009	2,285	751	1,532
Earnings From Equity Investments	293	166	-289	56	143	396
Currency Exchange Gain (Loss)	2,051	516	447	-	-	-
Other Non Operating Income (Expenses)	631	311	294	-64	245	260
EBT Excluding Unusual Items	47,208	40,431	42,432	35,568	29,083	23,910
Gain (Loss) on Sale of Investments	-617	1,896	-798	-160	-368	787
Gain (Loss) on Sale of Assets	-3	-	-	-	-	-
Asset Writedown	-35	-175	-348	-1,338	-892	-1,691
Other Unusual Items	57	179	230	219	129	-
Pretax Income	46,610	42,331	41,516	34,289	27,952	23,006
Income Tax Expense	11,719	11,379	10,123	7,860	6,803	6,236
Earnings From Continuing Operations	34,891	30,952	31,393	26,429	21,149	16,770
Minority Interest in Earnings	-350	54	-457	-52	-131	-27
Net Income	34,541	31,006	30,936	26,377	21,018	16,743
Net Income to Common	34,541	31,006	30,936	26,377	21,018	16,743
Net Income Growth	16.75%	0.23%	17.28%	25.50%	25.53%	8.65%
Shares Outstanding (Basic)	226	228	228	228	228	228
Shares Outstanding (Diluted)	232	229	229	229	229	229
Shares Change (YoY)	1.58%	0.04%	-	-0.00%	-	0.01%
EPS (Basic)	152.72	136.11	135.60	115.62	92.13	73.39
EPS (Diluted)	148.61	135.44	135.21	115.29	91.86	73.18
EPS Growth	14.93%	0.17%	17.28%	25.50%	25.53%	8.65%
Free Cash Flow	-	27,837	26,266	22,451	16,983	11,287
Free Cash Flow Per Share	-	121.61	114.80	98.13	74.23	49.33
Dividend Per Share	41.000	36.000	27.000	22.000	18.000	14.000
Dividend Growth	32.26%	33.33%	22.73%	22.22%	28.57%	7.69%
Gross Margin	56.13%	56.68%	58.07%	57.58%	58.35%	58.87%
Operating Margin	11.94%	12.46%	14.83%	14.05%	14.12%	12.06%
Profit Margin	10.29%	10.05%	11.42%	11.05%	10.53%	9.24%
Free Cash Flow Margin	-	9.02%	9.70%	9.41%	8.51%	6.23%
EBITDA	56,578	51,608	48,854	41,339	35,865	28,615
EBITDA Margin	16.85%	16.72%	18.04%	17.32%	17.96%	15.78%
D&A For EBITDA	16,485	13,143	8,687	7,801	7,673	6,748
EBIT	40,093	38,465	40,167	33,538	28,192	21,867
EBIT Margin	11.94%	12.46%	14.83%	14.05%	14.12%	12.06%
Effective Tax Rate	25.14%	26.88%	24.38%	22.92%	24.34%	27.11%
Advertising Expenses	-	57,506	54,219	46,467	38,114	40,525

Source: S&P Global Market Intelligence. Standard template. Financial Sources.